Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 3/20 | 0.41 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | HTR3A | P46098 | 1/20 | 0.36 |
| ▸ | PNMT | P11086 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NOS1 | P29475 | 1/20 | 0.35 |
| ▸ | NOS2 | P35228 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.34 |
| ▸ | PDE10A | Q9Y233 | 3/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1645280 | 0.79 | ALDH1A1 (0.48) | HTR3ANOS1ARALDH1A1CYP3A4 | |
| SCHEMBL21481511 | 0.78 | AR (0.42) | DPP4PDCD1LG2CD274HTR3APARP1 | |
| SCHEMBL28285434 | 0.77 | ALDH1A1 (0.40) | DPP4PDCD1LG2CD274ATRPARP1 | |
| SCHEMBL21483573 | 0.77 | NPC1 (0.47) | DPP4NOS2ARALDH1A1CYP3A4 | |
| SCHEMBL27610825 | 0.76 | NPC1 (0.46) | DPP4NOS2ARALDH1A1CYP3A4 | |
| Hydrochloric Acid SCHEMBL28782153 | 0.76 | MEN1 (0.49) | DPP4NOS3NOS1NOS2AR | |
| SCHEMBL2302216 | 0.74 | HTR3A (0.38) | PDCD1LG2CD274ATRHTR3APARP1 | |
| SCHEMBL31517113 | 0.73 | PARP1 (0.58) | HTR3APARP1ALDH1A1CYP3A4HPGD | |
| SCHEMBL1033940 | 0.73 | PARP1 (0.58) | HTR3APARP1ALDH1A1CYP3A4HPGD | |
| SCHEMBL27835947 | 0.71 | PDE10A (0.44) | HTR3APARP1PDE10AALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-20210139483-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES | LEAD DISCOVERY CENTER GMBH (DE) | 2021-05-13 | — | — | US | disclosed |
| WO-2019197546-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES | QURIENT CO., LTD. (KR) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | CDKL5, CDK15, CDK5 | DPP4 725/4885PDCD1LG2 2114/4885CD274 1365/4885 |
| US-20210139483-A1 | PHARMACEUTICALLY ACTIVE PYRAZOLO-TRIAZINE AND/OR PYRAZOLO-PYRIMIDINE DERIVATIVES | IL5, THPO, TYMP | DPP4 85/4885PDCD1LG2 2276/4885CD274 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.